| Ms Alicia Vera, | |
|
245 E 120th Street, Los Angeles, CA 90061 | |
| (760) 905-3009 | |
| Not Available |
| Full Name | Ms Alicia Vera |
|---|---|
| Gender | Female |
| Speciality | Counselor - Addiction (substance Use Disorder) |
| Location | 245 E 120th Street, Los Angeles, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003160003 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | CAS-12041 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Alicia Vera, 245 E 120th Street, Los Angeles, CA 90061 Ph: (760) 905-3009 | Ms Alicia Vera, 245 E 120th Street, Los Angeles, CA 90061 Ph: (760) 905-3009 |
News Archive
Loyola Medicine has launched a multidisciplinary Concussion Program to diagnose and treat concussions in athletes and other patients.
People who increased the amount of coffee they drank each day by more than one cup over a four-year period had a 11% lower risk for type 2 diabetes than those who made no changes to their coffee consumption, according to a new study led by Harvard School of Public Health (HSPH) researchers. In addition, the study found that those who decreased their coffee consumption by more than a cup per day increased their type 2 diabetes risk by 17%.
Nile Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that it has completed the dosing of the last patient in NIL-CDNP-CT005, an open-label, single-blind, placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure, or ADHF. The study was designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with ADHF and mild to moderate renal insufficiency.
The new influenza drug Xofluza, developed by the Japanese pharmaceutical company Shionogi, was approved for clinical use in Japan in February 2018.
› Verified 7 days ago
Angelica Oropeza, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1200 Wilshire Blvd, Los Angeles, CA 90017 Phone: 213-481-7464 Fax: 213-481-7147 | |
Tanya Sanderlin, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1147 S Alvarado St, Los Angeles, CA 90006 Phone: 213-381-8518 | |
Lionela Evers, Counselor Medicare: Not Enrolled in Medicare Practice Location: 5151 S Western Ave, Los Angeles, CA 90062 Phone: 818-997-6876 | |
Lori Miller, Counselor Medicare: Not Enrolled in Medicare Practice Location: 600 E 7th St, Los Angeles, CA 90021 Phone: 213-537-0110 Fax: 213-537-0880 | |
Kesha Williams, Counselor Medicare: Not Enrolled in Medicare Practice Location: 3761 Stocker St Ste 105, Los Angeles, CA 90008 Phone: 323-294-4261 | |
Genevieve Giselle Simari, PSY.D Counselor Medicare: Not Enrolled in Medicare Practice Location: 3787 S Vermont Ave, Los Angeles, CA 90007 Phone: 323-766-2345 | |
Sarah M. Powell, Counselor Medicare: Not Enrolled in Medicare Practice Location: 12714 Avalon Blvd, Los Angeles, CA 90061 Phone: 323-242-5000 |